Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you are going to post the rumor, you may as well post the source of the rumor as well.
Are we sure that QASP referred to a company and not the acronym, "Quality Assurance Surveillance Plan" ?
Any further information would be helpful.
The original NASDAQ IPO in May of 2013 was $8.90, I believe. But remember that wasn't the true IPO, this company has been trading publicly for around 15 years on the LSE.
Why? Looks primed to me.
I have no idea, but I found this on a British msg board from 9/14:
"barclays capitol have now pulled out, leaving only two companies left holding a significant short position...
DE shaw - 0.91
Healthcor management - 1.88"
New Study Results...Sativex Spray Effectively Reduces Spasticity in Patients with MS - See more at: http://www.hcplive.com/conferences/2014-ectrims/Sativex-Spray-Effectively-Reduces-Spasticity-in-Patients-with-MS#sthash.SXL9hRdN.dpuf
Silly article.
Why should cannabis only be considered an agricultural product? It should be considered as whatever it is being utilized for.
Shorts hard at work again, I see.
What Do You Guys Think About This…
http://www.freepatentsonline.com/y2014/0221469.html
I have no idea what earnings will look like, but check message #2593. If that is true GW should beat analyst predictions.
Sativex 2014 Growth
as per:
http://www.thepharmaletter.com/article/almiral-s-top-performing-product-in-first-half-of-2014-is-part-of-astrazeneca-selloff
(July 30th, 2014)
"Sativex (nabiximols), used for muscle spasms in multiple sclerosis, grew 78.5% against the first half of 2013."
$GWPH I've consulted the tarot cards...
Forbes article from 3 hours ago.
http://www.forbes.com/sites/davidkroll/2014/06/26/gw-pharmaceuticals-closes-u-s-public-offering-cannabid-based-medicines-progress/
Here is an excerpt:
In a commentary led by NYU’s Orrin Devinsky, M.D., Ph.D., a global collection of investigators come to a consensus that CBD has been incompletely investigated clinically due to poor trial design (i.e., unclear dosing regimens, improper study group sizes). But with the compelling preclinical studies and patient and caregiver anecdotes, CBD is certainly worthy of rigorous clinical investigation. Those hawking non-pharmaceutical CBD products might be dismayed to learn that several of the authors are collaborators of GW Pharmaceuticals and/or conducting GW-supported drug trials.
It would be very foolish to short this imho.
I've consulted my tarot cards and they showed me this
Forbes article from 3 hours ago.
http://www.forbes.com/sites/davidkroll/2014/06/26/gw-pharmaceuticals-closes-u-s-public-offering-cannabid-based-medicines-progress/
Here is an excerpt:
In a commentary led by NYU’s Orrin Devinsky, M.D., Ph.D., a global collection of investigators come to a consensus that CBD has been incompletely investigated clinically due to poor trial design (i.e., unclear dosing regimens, improper study group sizes). But with the compelling preclinical studies and patient and caregiver anecdotes, CBD is certainly worthy of rigorous clinical investigation. Those hawking non-pharmaceutical CBD products might be dismayed to learn that several of the authors are collaborators of GW Pharmaceuticals and/or conducting GW-supported drug trials.
It's not the plant that gets patented, it's the pharmaceutical's scientific name that does. The method of delivery is also patented. GWPH is THE company.
Important April Gap Filled
I think this has a chance of a slight pullback into 85 - 90 range sometime in next 2 weeks, then rips to 120 by late summer. But I guess we'll see...
Is that why GWP and GWPH are both up? lol
Be very careful shorting this.
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm401879.htm
Do you even understand why it dropped like that?
Most people had no idea what was going on in the mmj industry when that happened. That was before it was crystal clear, ie fast track, individual MOUs with states, backing from SAM. People were scared of SEC halts on all pot stocks. If you still think GW is apt to a halt, you are probably going to lose a lot [if not all] of your money. Don't go down on the long list of shorts/bashers who've gotten burned.
New York State Reaches Deal to Legalize Medical Marijuana
As per: http://online.wsj.com/articles/new-york-state-reaches-deal-to-legalize-medical-marijuana-1403207730
ALBANY—After nearly two decades of efforts to legalize the use of marijuana for medicinal purposes in New York state, Gov. Andrew Cuomo and legislative leaders on Thursday struck an agreement on a bill that will make certain forms of the drug available to patients with a limited range of diseases.
The bill, which still requires a vote by the state Legislature, will permit only doctors to prescribe marijuana in forms including oil-based and vapor to individuals with conditions including cancer, AIDS, epilepsy and multiple sclerosis.
But it won't legalize smokable forms of the drug, making it much narrower in scope than many other medical-marijuana legalization laws around the country. And it will allow the governor, upon recommendation by the state police superintendent or the state health commissioner, to suspend the program at any time.
While the bill's sponsors and patient advocates had pushed to permit smokable pot, Mr. Cuomo in recent days expressed concern about curbing what he described as marijuana's potential to become a "gateway" drug, a worry that was shared by some Republicans—including Senate Majority Coalition Co-leader Dean Skelos—whose votes were critical to the legislation's success.
The marijuana bill marks the rare occasion in which a piece of high-profile legislation will make its way to the governor's desk without a lengthy record of his fingerprints. While Mr. Cuomo exerted significant influence over the final product, the administration didn't become involved in shaping the bill until very late in the process, instead advocating for the governor's pilot program to introduce medical marijuana trials in a handful of state hospitals.
The bill now pending in the Legislature is largely the creation of its sponsors Sen. Diane Savino, a Staten Island Democrat, and Assemblyman Richard Gottfried, a Manhattan Democrat who has advocated for medical marijuana legalization for nearly 20 years. It was in the Senate, however, that the measure faced resistance, until both the politics surrounding the issue and the public support for the practice began to shift earlier this year.
In January, Mr. Cuomo introduced his own more limited effort to make pot available to the very ill, using an obscure 1980s law to set up a research program on marijuana, run by 20 hospitals around the state. But the sponsors of the full-scale legalization bill and patient advocates complained that the governor's plan wouldn't go far enough to help sick people.
In the months following Mr. Cuomo's proposal, a number of Republican senators who had previously opposed the legalization of marijuana for medical purposes said publicly that they would back the bill sponsored by Ms. Savino and Mr. Gottfried.
As support grew for that bill while the legislative session stretched to its final days, Mr. Cuomo's office became involved in talks to amend the legislation to allay some of the governor's concerns—primarily the removal of a provision that would allow smokable forms of the drug. Ms. Savino's bill had allowed health-care professionals to prescribe it in smokable form to patients over the age of 21.
The plan makes New York the 23rd state in the country to legalize at least some forms of marijuana for medicinal purposes, and the second—in addition to Minnesota—to do so while also banning smokable forms of the drug.
haha
A+ newmedman
and Ballgame, no worries.
Nice work. Be careful guys, a lot of misinformation floating around, even coming from more "reputable sources". People are stepping all over themselves to get into this one.
I think Ballgame is just throwing some misinformation out there. He only said stop trading prior to the pricing of the secondary. Secondary priced at $86.83. Resume trading.
Like I said before, albeit in different words... slightly below the current market price.
Ready for that spelling bee, Fung?
Haha, forget the spelling bee for a minute, Fung. Let's keep it mathematical. How do you get $150 mill from 1.7 million shares?
Oh yeah. Well that makes sense then, but that isn't what you were trying to peg on me at first. :)
I still hold by my prediction that the offering pps will be between $75 - $85.
English Lit 101
"but I can't see it being discounted much more than current market price"
In this statement, the author (me) is expressing the belief that yes, the price will be discounted (obviously) but not much under the current market price [if $150 mill or close is to be made on 1.7 mill shares].
Yes, as I wrote it would. But do the math yourself, the shares aren't going to be discounted too much if they really want close to $150 mill. Fung, you are better than this.
"GW said on Wednesday that it planned to sell 1.7m American Depositary Shares in its latest offering. The price has not been set but people close to the company said the target was to raise about $150m."
150,000,000 / 1,700,000 = $88.2353
I realize there are other factors that come into play, but I can't see it being discounted much more than current market price ($87.53).
What problem with NYC?
Cuomo / NY state signed a deal with GWPH last week.
I think the catalysts for the next cpl months will be these individual state deals that are happening with GW Pharma (first GA now NY). I'd like to see some sort of approval(s) prior to June 1st, 2015, as this is when MN said their CBD oil legislation goes into effect.
[I] loved today's green action after a great Fri and Mon.
New York Partners with GW Pharmaceuticals
as per: http://online.wsj.com/article/APcb96095ed94543a6aa6337df1f8bdcdd.html
ALBANY, N.Y. — New York state is partnering with a British company to hold clinical trials for marijuana-based medication for children who have seizures that are resistant to their medicine.
An agreement was signed on Sunday between Gov. Andrew Cuomo's administration and GW Pharmaceuticals. The state health department and the company will develop the framework for a clinical trial for a marijuana-based drug for people under the age of 18.
It will involve Epidiolex, an investigational medication that uses cannabidiol, a marijuana extract that doesn't get users high. It could help children with rare forms of epilepsy such as Dravet and Lennox-Gastaut syndromes.
Dravet syndrome is a rare genetic disorder typically untreatable by anti-epileptic drugs. It can be fatal. Lennox-Gastaut syndrome, another rare form of childhood- onset epilepsy, is characterized by different types of seizures multiple times a day and cognitive dysfunction. To be eligible for the trial, the children would have to show signs that their current medication is not working.
The health department is working on the framework for the protocol, which needs to be approved by the Food and Drug Administration before it is enacted. A state official with knowledge of the agreement told The Associated Press on Monday they expect FDA approval relatively quickly. The official spoke on condition of anonymity because the official was not authorized to speak publicly about the agreement.
In Colorado, the Charlotte's Web strain of marijuana, which is high in cannabidiol content, has received international attention for its effect on children with severe seizures. It also is low in the chemical responsible for most of marijuana's psychological effects. The Realm of Caring, a non-profit organization which produces the strain, currently has 206 people on its waiting list in the United States and separate waiting lists worldwide.
The announcement of the agreement with GW Pharmaceuticals comes as medical marijuana legislation is being pushed into the forefront of New York state politics.
In January, Cuomo, a Democrat, proposed a pilot program to allow 20 hospitals statewide to administer medical marijuana to seriously ill patients under the health department's guidelines.
The Legislature also is considering two medical marijuana bills. One called the "Compassionate Care Act" is making its way through the Republican-led Senate. It would allow patients with one of 20 serious illnesses to use the drug. The bill would bar anyone under the age of 21 from smoking marijuana, but would allow the drug to be administered through a vaporizer, oil or something edible.
Another measure would prohibit smoking the drug in its entirety, but legalize medical marijuana use in vaporizer, oil or edible form for seriously ill patients.
In his original article
he does state $44 mill for a yearly revenue summation, but still, really?
Very disingenuous.
Motley Fool Hit Piece
Sean Williams writes: GWPH's 2013 yearly revenue was $3.7 million. He also goes on to state that this product has "been on the EU market for years".
Sean Williams' deep hole of lies makes me very confident in my long position here.
Some valuation numbers I have heard thrown around..
Peak sales of Sativex = $800 million
Peak sales of Epidiolex = $1 billion - $1.5 billion
Price targets now around $100 - $105
I've also heard, in the best case scenarios that if Sativex, Epidiolex, and a couple other medications in the pipeline succeed, and they get true market penetration this stock could be around $330 per share someday. Of course that is assuming all of the stars lineup perfectly.
New York Partners with GW Pharmaceuticals
as per: http://online.wsj.com/article/APcb96095ed94543a6aa6337df1f8bdcdd.html
ALBANY, N.Y. — New York state is partnering with a British company to hold clinical trials for marijuana-based medication for children who have seizures that are resistant to their medicine.
An agreement was signed on Sunday between Gov. Andrew Cuomo's administration and GW Pharmaceuticals. The state health department and the company will develop the framework for a clinical trial for a marijuana-based drug for people under the age of 18.
It will involve Epidiolex, an investigational medication that uses cannabidiol, a marijuana extract that doesn't get users high. It could help children with rare forms of epilepsy such as Dravet and Lennox-Gastaut syndromes.
Dravet syndrome is a rare genetic disorder typically untreatable by anti-epileptic drugs. It can be fatal. Lennox-Gastaut syndrome, another rare form of childhood- onset epilepsy, is characterized by different types of seizures multiple times a day and cognitive dysfunction. To be eligible for the trial, the children would have to show signs that their current medication is not working.
The health department is working on the framework for the protocol, which needs to be approved by the Food and Drug Administration before it is enacted. A state official with knowledge of the agreement told The Associated Press on Monday they expect FDA approval relatively quickly. The official spoke on condition of anonymity because the official was not authorized to speak publicly about the agreement.
In Colorado, the Charlotte's Web strain of marijuana, which is high in cannabidiol content, has received international attention for its effect on children with severe seizures. It also is low in the chemical responsible for most of marijuana's psychological effects. The Realm of Caring, a non-profit organization which produces the strain, currently has 206 people on its waiting list in the United States and separate waiting lists worldwide.
The announcement of the agreement with GW Pharmaceuticals comes as medical marijuana legislation is being pushed into the forefront of New York state politics.
In January, Cuomo, a Democrat, proposed a pilot program to allow 20 hospitals statewide to administer medical marijuana to seriously ill patients under the health department's guidelines.
The Legislature also is considering two medical marijuana bills. One called the "Compassionate Care Act" is making its way through the Republican-led Senate. It would allow patients with one of 20 serious illnesses to use the drug. The bill would bar anyone under the age of 21 from smoking marijuana, but would allow the drug to be administered through a vaporizer, oil or something edible.
Another measure would prohibit smoking the drug in its entirety, but legalize medical marijuana use in vaporizer, oil or edible form for seriously ill patients.
Nope, maybe you are confusing that with 24.19%, which was the actual increase in institutional ownership, reported on the last 13-f.
http://www.j3sg.com/Reports/Stock-Insider/generate-Institution.php?tickerLookUp=GWPH&pageNumber=1&descending=1&sortBy=value
http://www.streetinsider.com/holdings.php?q=GWPH
There are no numbers out yet for the time period you speak of. Nice try though.
Bad short. Those numbers are flat out wrong.
It's been figured it out.
Look at: http://www.nasdaq.com/symbol/gwph/ownership-summary
They are making a mistake in the ADR conversion.
1 GWPH = 12 GWP.L
% of shares outstanding: 3.48%
Total shares held: 7,527,683
Total Value of Holdings: 517,603,483
The float on GWP.L is 200 million shares or something
GWPH is like 15 million.
They are mistakenly dividing the 7,527,683 shares of GWPH (owned institutionally) by the 200,000,000 float of GWP, and not the 15-20 million share float of GWPH. Look at the total value of holdings, it is over half a billion. 50%+ of GWPH is institutionally owned. Take that to the bank.
GW Pharmaceutical's MOU with State of Georgia
As per: http://www.twst.com/update/61491-gw-pharmaceuticals-plc-gw-pharmaceuticals-announcement-regarding-mou-with-state-of-georgia
Atlanta, Georgia, and London, UK 27 May 2014: A State of Georgia initiative making it possible to treat children with epilepsy with cannabidiol is moving forward. The state, GW Pharmaceuticals (NASDAQ: GWPH), and Georgia Regents University Augusta (GRU), announced today that they have entered into a Memorandum of Understanding to study GW's investigational cannabidiol (CBD) product Epidiolex® in the treatment of children with medication-resistant epilepsies.
Georgia Governor Nathan Deal announced in April his support for clinical research that would investigate the use of CBD, a non-psychoactive component of the cannabis plant, and develop rigorous data that will inform and expand the scientific community's understanding of potential treatments for difficult-to-treat forms of childhood epilepsies. Deal's commitment to this research has led to this plan to form collaboration between GRU and GW Pharmaceuticals. It is expected that details of the collaboration will be finalized in the coming months in order for research to commence later this year.
As you were saying, Cal...
lol What does that have to do with GWPH's merit?
That they were mentioned in the same investing article as penny stocks? It's because those are the only other public plays in the mmj sector.
No volume compared to when?
This stock was trading under 10k some days last year.
Yes Institutional Holdings
are around 3.45%, can you site the drop from 30% to 3.45% ?
Green2013...
LOL
"A POS diluting scam machine" with 73 institutional holders that reads something like:
Prudential
Capital Research Management
VHCP
Franklin Resources
Federated Investors
Redmile
Wells Fargo & Company
Price T Rowe Associates
AllianceBernstein
Janus Capital Management
Morgan Stanley
etc.
I'm sure you get the picture. Don't come here and be a clown.